Update of MuSK Myasthenia Gravis Phase 1 Clinical Trial (MusCAARTes)
Oct 11th | 2pm (Eastern) 11am (Pacific)
– Review of data that supported IND submission and clearance by the FDA
– Discuss the purpose of clinical trials
– Present the design of the MusCAARTes Phase 1 clinical trial for patients with MuSK Myasthenia Gravis
The presenter will be David Chang, M.D., M.P.H., Chief Medical Officer at Cabaletta Bio.
Watch here: